Point-of-care assessment of antiplatelet agents in the perioperative period: A review

Anaesthesia and Intensive Care

Volumn 37, Issue 3, 2009, Pages 354-369

  Gibbs, N M ^a  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

Anti platelet agents; Assessment; Platelet function; Point of care; Thrombelastography

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; EPTIFIBATIDE; NONSTEROID ANTIINFLAMMATORY AGENT; TICLOPIDINE; TIROFIBAN;

ANESTHESIA; BLOOD CLOTTING; BLOOD CLOTTING PARAMETERS; DEVICE; DRUG ACTIVITY; DRUG SENSITIVITY; HEMOSTASIS; HUMAN; PERIOPERATIVE PERIOD; POINT OF CARE TESTING; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTE FUNCTION; THROMBOELASTOGRAPHY;

EID: 66249112162     PISSN: 0310057X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0310057x0903700317     Document Type: Review

References (105)

1. Chassot PG, Delabays A, Spahn DR. Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction. Br J Anaesth 2007; 99:316-328. (Pubitemid 47321534)
2. Howard-Alpe GM, de Bobo J, Hudsmith L, Orr WP, Foex P, Sear JW. Coronary artery stents and non-cardiac surgery. Br J Anaesth 2007; 98:560-574. (Pubitemid 47078669)
3. Newsome LT, Weller RS, Gerancher JC, Kutcher MA, Royster RL. Coronary artery stents: II. Perioperative considerations and management. Anesth Analg 2008; 107:570-590.
4. Samama CM, Bastien O, Forestier F, Denninger MH, Isetta C, Juliard JM et al. Antiplatelet agents in the perioperative period: expert recommendations of the French Society of Anesthesiology and Intensive Care (SFAR) 2001 - summary statement. Can J Anaesth 2002; 49:S26-35.
5. Horlocker TT, Wedel DJ, Benzon H, Brown DL, Enneking FK, Heit JA et al. Regional anesthesia in the anticoagulated patient: Defining the risks (the second ASRA consensus conference on neuraxial anesthesia and anticoagulation). Reg Anesth Pain Med 2003; 28:172-197.
6. Kovesi T, Royston D. Is there a bleeding problem with platelet active drugs? Br J Anaesth 2002; 88:159-163.
7. Pamukcu B. A review of aspirin resistance: definition, possible mechanisms, detection with platelet function tests, and its clinical outcomes. J Thromb Thrombolysis 2007; 23:213-222. (Pubitemid 46564122)
8. Cattaneo M. Aspirin and clopidogrel: Efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004; 24:1980-1987. (Pubitemid 39482419)
9. Peerschke EIB. The laboratory evaluation of platelet dysfunction. Clin Lab Med 2002; 22:405-420. (Pubitemid 34755911)
10. Seegmiller A, Sarode R. Laboratory evaluation of platelet function. Hematol Oncol Clin North Am 2007; 21:731-742.
11. Harrison P. Platelet function analysis. Blood Reviews 2005; 19:111-123. (Pubitemid 39643116)
12. Nylander S, Johansson K, Van Giezen JJJ, Lindahl TL. Evaluation of platelet function, a method comparison. Platelets 2006; 17:49-55. (Pubitemid 41759241)
13. George JN. Platelets. Lancet 2000; 355:1531-1539.
14. Andrews RK, Berndt MC. Platelet physiology and thrombosis. Thromb Res 2004; 114:447-453. (Pubitemid 39422578)
15. Troxler M, Dickinson K, Homer-Vanniasinkam S. Platelet function and antiplatelet therapy. Br J Surg 2007; 94:674-682. (Pubitemid 46910058)
16. Offermans S. Activation of platelet function through G protein coupled receptors. Circ Res 2006; 99:1293-1304.
17. Dorsam RT, Kunapuli SP. Central role of the P2Y12 receptor in platelet activation. J Clin Invest 2004; 113:340-345. (Pubitemid 38544175)
18. Kroll MH, Schafer AI. Biochemical mechanisms of platelet activation. Blood 1989; 74:1181-1195. (Pubitemid 19227423)
19. Verstraete M. Synthetic inhibitors of platelet glycoprotein IIb/IIIa in clinical development. Circulation 2000; 101:E76-80.
20. Kam PCA, See Au-L. Cyclooxygenase isoenzymes: physiological and pharmacological role. Anaesthesia 2000; 55:442-449. (Pubitemid 30301443)
21. Shafer AI. Antiplatelet therapy. Am J Med 1996; 101:199-209. (Pubitemid 26296782)
22. Grosser T. The pharmacology of selective inhibition of COX-2. Thromb Haemost 2006; 96:391-392. (Pubitemid 44560671)
23. Shafer AI. Effects of nonsteroidal anti-inflammatory therapy on platelets. Am J Med 1999; 106:25S-36S.
24. Kam PCA, Nethery CM. The thienopyridine derivatives (platelet adenosine diphosphate receptor antagonists), pharmacology and clinical developments. Anaesthesia 2003; 58:28-35. (Pubitemid 36113325)
25. Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation 1999; 100:1667-1672.
26. Kam PCA, Egan MK. Platelet glycoprotein IIb/IIIa antagonists: Pharmacology and clinical developments. Anesthesiology 2002; 96:1237-1249. (Pubitemid 34462587)
27. Mallett SV, Cox DJA. Thrombelastography. Br J Anaesth 1992; 69:307-313.
28. Gibbs NM, Sear JW. Effect of ketorolac, bupivacaine and low-dose heparin on thrombelastographic variables in vitro. Br J Anaesth 1995; 75:27-30.
29. Tuman KJ, McCarthy RJ, Djuric M, Rizzo V, Ivankovich AD. Evaluation of coagulation during cardiopulmonary bypass with a heparinase-modified thromboelastographic assay. J Cardiothorac Vasc Anesth 1994; 8:144-149. (Pubitemid 24118390)
30. Trentalange MJ, Walts LF. A comparison of thromboelastogram and template bleeding time in the evaluation of platelet function after aspirin ingestion. J Clin Anesth 1991; 3:377-381.
31. Orlikowski CEP, Payne AJ, Moodley J, Rocke DA. Thrombelastography after aspirin ingestion in pregnant and non-pregnant subjects. Br J Anaesth 1992; 69:159-161.
32. Samama CM. Should a normal thromboelastogram allow us to perform a neuraxial block? A strong word of warning. Can J Anesth 2003; 50:761-763. (Pubitemid 37455528)
33. Tanaka KA, Szlam F, Kelly AB, Vega JD, Levy JH. Clopidogrel (Plavix) and cardiac surgical patients: implications for platelet function monitoring and postoperative bleeding. Platelets 2004; 15:325-332. (Pubitemid 39037135)
34. Herbstreit F, Peters J. Spinal anaesthesia despite combined clopidogrel and aspirin therapy in a patient awaiting lung transplantation: effects of platelet transfusion on clotting tests. Anaesthesia 2005; 60:85-87. (Pubitemid 40081246)
35. Craft RM, Chavez JJ, Snider CC, Muenchen RA, Carroll RC. Comparison of modified Thrombelastograph and Plateletworks whole blood assays to optical platelet aggregation for monitoring reversal of clopidogrel inhibition in elective surgery patients. J Lab Clin Med 2005; 145:309-315. (Pubitemid 40835883)
36. Bowbrick VA, Mikhailidis DP, Stansby G. Value of thromboelastography in the assessment of platelet function. Clin Appl Thromb Hemost 2003; 9:137-142. (Pubitemid 36665981)
37. Bailey LA, Sistino JJ, uber WE. Is platelet function as measured by thrombelastograph monitoring in whole blood affected by platelet inhibitors? J Extra-Corpor Technol 2005; 37:43-47.
38. Katori N, Szlam F, Levy JH, Tanaka KA. A novel method to assess platelet inhibition by eptifibatide with Thrombelastograph®. Anesth Analg 2004; 99:1794-1799. (Pubitemid 39551922)
39. Nielsen VG. A comparison of the thrombelastograph and the ROTEM. Blood Coagul Fibrinolysis 2007; 18:247-252. (Pubitemid 46597397)
40. Hett DA, Walker D, Pilkington SN, Smith DC. Sonoclot analysis. Br J Anaesth 1995; 75:771-776.
41. Samra SK, Harrison RL, Bee DE, Valero V. A study of aspirin induced changes on bleeding time, platelet aggregation, and Sonoclot coagulation analysis in humans. Ann Clin Lab Sci 1991; 21:315-327.
42. Stern MP, de Vos-Doyle K, Viguera MA, Lajos TZ. Evaluation of post-cardiopulmonary bypass Sonoclot signatures in patients taking nonsteroidal anti-inflammatory drugs. J Cardiothorac Anesth 1989; 3:730-733. (Pubitemid 20029351)
43. Horlocker TT, Schroeder DR. Effect of age, gender, and platelet count on Sonoclot coagulation analysis in patients undergoing orthopaedic operations. Mayo Clin Proc 1997; 72:214-219. (Pubitemid 28196622)
44. Tucci MA, Ganter MT, Haamiel CR, Klaghofer R, Zollinger A, Hofer CK. Platelet function monitoring with the Sonoclot analyser after in vitro tirofiban and heparin administration. J Thorac Cardiovasc Surg 2006; 131:1314-1322. (Pubitemid 43776062)
45. McKenzie ME, Gurbel PA, Douglas DJ, Serebruany VL. Clinical utility of available methods for determining platelet function. Cardiology 1999; 92:240-247. (Pubitemid 30209737)
46. Berkowitz SD, Frelinger III AL, Hillman RS. Progress in point-of-care laboratory testing for assessing platelet function. Am Heart J 1998; 136:S51-S65. (Pubitemid 28487159)
47. Rochon AG, Shore-Lesserson L. Coagulation monitoring. Anesthesiol Clin 2006; 24:839-856.
48. Greilich PE, Alving BM, Longnecker D, Carr ME Jr, Whitten CW, Chang AS et al. Near-site monitoring of the antiplatelet drug abciximab using the Hemodyne analyser and modified thrombelastograph. J Cardiothorac Vasc Anesth 1999; 13:58-64. (Pubitemid 29095908)
49. Michelson AD, Frelinger AL, Furman MI. Current options in platelet function testing. Am J Cardiol 2006; 98:4N-10N.
50. Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007; 50:1822-1834. (Pubitemid 350007957)
51. Faraday N, Guallar E, Sera VA, Bolton ED, Scharpf RB, Cartarius AM et al. utility of whole blood hemostatometry using the Clot Signature Analyzer® for the assessment of hemostasis in cardiac surgery. Anesthesiology 2002; 96:1115-1122. (Pubitemid 34462572)
52. Fricke W, Kouides P, Kessler C, Schmaier AH, Krijanovski Y, Jagadeesan K et al. A multicenter clinical evaluation of the Clot Signature Analyzer. J Thromb Haemost 2004; 2:763-768. (Pubitemid 40185715)
53. Haddadin AS, Ayoub CM, Sevarino FB, Rinder CS. Evaluation of hemostasis by the clot signature snalyzer: a potentially valuable device for the anesthesiologist. J Clin Monit Comput 1999; 15:125-129. (Pubitemid 29278443)
54. Griffin MJ, Rinder HM, Smith BR, Tracey JB, Kriz NS, Li CK et al. The effects of heparin, protamine, and heparin/protamine reversal on platelet function under conditions of arterial shear stress. Anesth Analg 2001; 93:20-27. (Pubitemid 32601145)
55. Valeri CR, Ragno G. In vitro testing of platelets using the thromboelastogram, platelet function analyzer, and the clot signature analyser to predict the bleeding time. Transfus Apher Sci 2006; 35:33-41.
56. Igawa T, Kornhauser R, Cilla DD, King JO, Kambayashi J. Evaluation of the Clot Signature Analyzer as a hemostasis test in healthy volunteers exposed to low doses of aspirin. Clin Appl Thromb Hemost 1999; 5:117-121. (Pubitemid 29165343)
57. Simon DI, Liu CB, Ganz P, Kirshenbaum JM, Piana RN, Rogers C et al. A comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofiban. Catheter Cardiovasc Interv 2001; 52:425-432. (Pubitemid 32275029)
58. Harrison P. Progress in the assessment of platelet function. Br J Haematol 2000; 111:733-744. (Pubitemid 32098909)
59. Mukherjee D, Moliterno DJ. Monitoring antiplatelet therapy: what is the best method? Clin Pharmacokinet 2000; 39:445-458.
60. Despotis GJ, Levine V, Filos KS, Santoro SA, Joist JH, Spitznagel E et al. Evaluation of a new point-of-care test that measures PAF-mediated acceleration of coagulation in cardiac surgical patients. Anesthesiology 1996; 85:1311-1323. (Pubitemid 27014658)
61. Ereth MH, Nuttall GA, Klindworth JT, MacVeigh I, Santrach PJ, Orszulak TA et al. Does the platelet-activated clotting test (hemoSTATUS®) predict blood loss and platelet dysfunction associated with cardiopulmonary bypass? Anesth Analg 1997; 85:259-265.
62. Isgro F, Rehn F, Kiessing AF, Kretz KU, Killian W, Saggau W. Platelet function test HemoSTATUS 2: tool or toy for an optimised management of haemostasis? Perfusion 2002; 17:27-31.
63. Harrison P. The role of the PFA-100® testing in the investigation and management of haemostatic defects in children and adults. Br J Haematol 2005; 130:3-10. (Pubitemid 40979127)
64. Hayward CPM, Harrison P, Cattaneo M, Ortel TL, Rao AK. Platelet function analyser (PFA)-100® closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006; 4:312-319. (Pubitemid 43756735)
65. Marshall PW, Williams AJ, Dixon RM, Growcott JW, Warburton S, Armstrong J et al. A comparison of the effects of aspirin on bleeding time measured using the Simplate™ method and closure time measured using the PFA-100®, in healthy volunteers. Br J Clin Pharmacol 1997; 44:151-155. (Pubitemid 27327067)
66. Mammen EF, Comp PC, Gosselin R, Greenberg C, Hoots WK, Kessler CM et al. PFA-100™ system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998; 24:195-202. (Pubitemid 28180831)
67. Blaicher AM, Landsteiner HT, Zwerina J, Leitgeb U, Volf I, Hoerauf K. Effect of non-selective, non-steroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors on the PFA-100 closure time. Anaesthesia 2004; 59:1100-1103. (Pubitemid 39429874)
68. Coakley M, Self R, Marchant W, Mackie I, Mallett SV, Mythen M. use of the platelet function analyser (PFA-100®) to quantify the effect of low dose aspirin in patients with ischaemic heart disease. Anaesthesia 2005; 60:1173-1178. (Pubitemid 41762838)
69. Gibbs NM, Weightman WM, Thackray NM, Michalopoulos N, Weidman C. The effects of recent aspirin ingestion on platelet function in cardiac surgical patients. J Cardiothorac Vasc Anesth 2001; 15:55-59. (Pubitemid 32172684)
70. Agarwal S, Coakely M, Reddy K, Riddell A, Mallett S. Quantifying the effect of antiplatelet therapy: A comparison of the platelet function analyser (PFA-100®) and modified thromboelastography (mTEG®) with light transmission platelet aggregometry. Anesthesiology 2006; 105:676-683. (Pubitemid 44477312)
71. Paniccia R, Antonucci E, Gori AM, Marcucci R, Poli S, Romano E et al. Comparison of different methods to evaluate the effect of aspirin on platelet function in high-risk patients with ischemic heart disease receiving dual antiplatelet therapy. Am J Clin Pathol 2007; 128:143-149. (Pubitemid 47121727)
72. Van der Planken MG, Claeys MJ, Vertessen FJ, Dilling D, Bosmans JM, Berneman ZN et al. Comparison of turbidometric aggregation and in vitro bleeding time (PFA-100) for monitoring the platelet inhibitory profile of antiplatelet agents in patients undergoing stent implantation. Thromb Res 2003; 111:159-164. (Pubitemid 37532854)
73. Mueller T, Haltmayer M, Poelz W, Haidinger D. Monitoring aspirin 100 mg and clopidogrel 75 mg therapy with the PFA-100 device in patients with peripheral arterial disease. Vasc Endovascular Surg 2003; 37:117-123. (Pubitemid 36373475)
74. Alstrom U, Tyden H, Oldgren J, Siegbahn A, Stahle E. The platelet inhibiting effect of a clopidogrel bolus dose in patients on long-term acetylsalicylic acid treatment. Thromb Res 2007; 120:323-359. (Pubitemid 46881256)
75. Jaremo P, Lindahl TL, Fransson SG, Richter A. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 2002; 252:233-238.
76. Madan M, Berkowitz SD, Christie DJ, Jennings LK, Smit AC, Sigmon KN et al. Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention. Am Heart J 2001; 141:226-233. (Pubitemid 32128727)
77. Madan M, Berkowitz SD, Christie DJ, Smit AC, Sigmon KN, Tcheng JE. Determination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100. Am Heart J 2002; 144:151-158. (Pubitemid 34734769)
78. Lau WC, Walker CT, Obilby D, Wash MM, Carville DG, Guyer KE et al. Evaluation of a BED-SIDE platelet function assay: performance and clinical utility. Ann Card Anaesth 2002; 5:33-42.
79. Carville DG, Schleckser PA, Guyer KE, Corsello M, Walsh MM. Whole blood platelet function assay on the ICHOR point-of-care hematology analyser. J Extra-Corpor Technol 1998; 30:171-177. (Pubitemid 29152672)
80. Lennon MJ, Gibbs NM, Weightman WM, McGuire D, Michalopoulos N. A comparison of PlateletWorks™ and platelet aggregometry for the assessment of aspirin-related platelet dysfunction in cardiac surgical patients. J Cardiothorac Vasc Anesth 2004; 18:136-140. (Pubitemid 38506856)
81. Mobley JE, Bresee SJ, Wortham DC, Craft RM, Snider CC, Carroll RC. Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization. Am J Cardiol 2004; 93:456-458. (Pubitemid 38221356)
82. Tanaka KA, Katori N, Szlam F, Sato N, Kelly AB, Levy JH. Effects of tirofiban on haemostatic activation in vitro. Br J Anaesth 2004; 93:263-269. (Pubitemid 39117402)
83. White MM, Krishnan R, Kueter TJ, Jacoski MV, Jennings LK. The use of the point of care Helena ICHOR/Plateletworks® and the Accumetrics ultegra® RPFA for assessment of platelet function with GpIIb-IIIa antagonists. J Thromb Thrombolysis 2004; 18:163-169. (Pubitemid 40552930)
84. Smith JW, Steinhubl SR, Lincoff AM, Coleman JC, Lee TT, Hillman RS et al. Rapid platelet-function assay: An automated and quantitative cartridge based method. Circulation 1999; 99:620-625. (Pubitemid 29077360)
85. Gurbel PA, Bliden KP, DiChiara J, Newcomer J, Weng W, Neerchal NK et al. Evaluation of dose-related effects of aspirin on platelet function: results from the aspirin-induced platelet effect (ASPECT) study. Circulation 2007; 115:3156-3164. (Pubitemid 47012230)
86. Malinin A, Pokov A, Spergling M, Defranco A, Schwartz K, Schwartz D et al. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study. Thromb Res 2007; 119:277-284.
87. Wheeler GL, Braden GA, Steinhubl SR, Kereiakes DJ, Kottke-Marchant K, Michelson AD et al. The ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy. Am Heart J 2002; 143:602-611. (Pubitemid 34454692)
88. Siota A, Buckland R, Judge HM, Sastry P, Storey RF. utility of a whole blood single platelet counting assay to monitor the effects of tirofiban in patients with acute coronary syndromes scheduled for coronary intervention. Thromb Haemost 2006; 95:997-1002. (Pubitemid 43933757)
89. Lordkipanidze M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007; 28:1702-1708. (Pubitemid 47227104)
90. Harrison P, Segal H, Blasberry K, Furtado C, Silver L, Rothwell PM. Screening for aspirin responsiveness after transient ischemic attack and stroke: Comparison of 2 point-of-care platelet function tests with optical aggregometry. Stroke 2005; 36:1001-1005. (Pubitemid 40629292)
91. Malinin A, Pokov A, Swaim L, Kotob M, Serebruany V. Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel. Methods Find Exp Clin Pharmacol 2006; 28:315-322. (Pubitemid 44047198)
92. Jakubowski JA, Payne CD, Li YG, Brandt JT, Small DS, Farid NA et al. The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration. Thromb Haemost 2008; 99:409-415.
93. Paniccia R, Antonucci E, Gori AM, Marcucci R, Giglioli C, Antoniucci D et al. Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J Thromb Haemost 2007; 5:1839-1847. (Pubitemid 47288940)
94. Hochholzer W, Trenk D, Frundi D, Neumann F-J. Whole blood aggregometry for evaluation of the antiplatelet effects of clopidogrel. Thromb Res 2007; 119:285-291.
95. Lordkipanidze M, Pharand C, Nguyen TA, Schampaert E, Diodati JG. Assessment of VerifyNow P2Y12 assay accuracy in evaluating clopidogrel-induced platelet inhibition. Ther Drug Monit 2008; 30:372-378.
96. Varon D, Lashevski I, Brenner B, Beyar R, Lanir N, Tamarin I et al. Cone and plate(let) analyser: monitoring glycoprotein IIb/IIIa antagonists and von Willebrand disease replacement therapy by testing platelet deposition under flow conditions. Am Heart J 1998; 135:S187-193. (Pubitemid 28237293)
97. Spectre G, Brill A, Gural A, Shenkman B, Touretsky N, Mosseri E et al. A new point-of-care method for monitoring anti-platelet therapy: application of the cone and plate(let) analyzer. Platelets 2005; 16:293-299. (Pubitemid 40943924)
98. Osende JI, Fuster V, Lev EI, Shimbo D, Rauch U, Marmur JD et al. Testing platelet activation with a shear-dependent platelet function test versus aggregation based tests. Circulation 2001; 103:1488-1491.
99. Craft RM, Chavez JJ, Bressee SJ, Wortham DC, Cohen E, Carroll RC. A novel modification of the thrombelastograph assay, isolating platelet function, correlates with optical platelet aggregation. J Lab Clin Med 2004; 143:301-309. (Pubitemid 38586495)
100. Hobson AR, Agarwala RA, Swallow RA, Dawkins KD, Curzen NP. Thrombelastography: current clinical applications and its potential role in interventional cardiology. Platelets 2006; 17:509-518.
101. Bochsen L, Wiinberg B, Kjelgaard-Hansen M, Steinbruchel DA, Johansson PI. Evaluation of the TEG® platelet mappingTM assay in blood donors. Thrombosis Journal 2007; 5:3. (Pubitemid 46351585)
102. Swallow RA, Argawala RA, Dawkins KD, Curzen NP. Thromboelastography: potential bedside tool to assess the effects of antiplatelet therapy? Platelets 2006; 17:385-392.
103. Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 2005; 46:1710-1711.
104. Lev EI, Ramchandani M, Garg R, Wojciechowski Z, Builes A, Vaduganathan M et al. Response to aspirin and clopidogrel in patients scheduled to undergo cardiovascular surgery. J Thromb Thrombolysis 2007; 24:15-21. (Pubitemid 46831559)
105. Hobson AR, Petley GW, Dawkins KD, Curzen N. A novel fifteen minute test for assessment of individual time-dependent clotting responses to aspirin and clopidogrel using modified thrombelastography. Platelets 2007; 18:497-505. (Pubitemid 350034856)